FIELD: biotechnology.
SUBSTANCE: following is proposed: a mouse monoclonal antibody 5B9 that neutralizes Ricinus communis ricin, specifically binds to the Ricinus communis ricin toxin in region A of the chain and is represented by two identical light and two identical heavy chains forming an IgG1 molecule, with light chain amino acid sequences of the following SEQ ID NO: 1 and Fd heavy chain fragment of the following SEQ ID NO: 2. Also the following is proposed: a strain of Mus musculus hybrid cultivated animal cells deposited in the state collection of pathogenic microorganisms and cell cultures "GKPM-Obolensk" No. H-97, producing the above antibody 5B9. Also a chimeric recombinant mouse-human monoclonal antibody xi5B9 obtained by replacing the light and heavy chain constant domains of the above 5B9 antibody is provided. The xi5B9 antibody neutralizes Ricinus communis ricin, specifically binds to the Ricinus communis ricin toxin in region A of the chain, is expressed in eukaryotic cells of the ExpiCHO-S line, and is characterized by an equilibrium dissociation constant of 2.63×10-8. The xi5B9 antibody is represented by two identical light chains and two identical heavy chains carrying human immunoglobulin G1 constant domains, forming an IgG1 molecule with light chain amino acid sequences of the following SEQ ID NO: 3 and heavy chain of the following SEQ ID NO: 4.
EFFECT: invention provides production of antibodies with high affinity and highly specific binding to chain A of Ricinus communis ricin toxin, which have a neutralizing effect on Ricinus communis ricin toxin.
3 cl, 12 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| ANTIBODIES AGAINST HUMAN STABILIN-1 RECEPTOR | 2023 |
|
RU2823309C1 |
| 1E10 MONOCLONAL MOUSE ANTIBODY 1E10 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI1E10, NEUTRALIZING BACILLUS ANTHRACIS LETHAL TOXIN, AND A STRAIN OF HYBRID CULTURED ABIMAL CELLS -MUS MUSCULUS 1E10 | 2020 |
|
RU2745116C1 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| METHOD OF PRODUCING MOUSE MODEL FOR STUDYING DUCHENNE MUSCULAR DYSTROPHY AND VERSIONS OF ITS THERAPY | 2023 |
|
RU2815936C1 |
| VIRUS-LIKE CHIMERIC PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 CONTAINING CORONAVIRUS AND ROTAVIRUS PROTEINS | 2022 |
|
RU2779810C1 |
